Business Context and Reporting Period
The supplied filing is Cerecor Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2016—not a filing identified as Avalo Therapeutics. Cerecor was a clinical-stage biopharmaceutical company developing treatments for neurological and psychiatric disorders. Its candidates included CERC-301 and CERC-501, both in Phase 2 development, and preclinical candidate CERC-406. It reported no product revenue.
Financial Results and Liquidity
| Metric | Q1 2016 | Q1 2015 or comparison |
|---|---|---|
| Revenue | None | None reported |
| Research and development expense | $2.29 million | $1.72 million |
| General and administrative expense | $2.65 million | $0.76 million |
| Operating loss | $4.94 million | $2.48 million |
| Net loss | $5.14 million | $3.24 million |
| Net loss per share, basic and diluted | $0.59 | $4.98 |
| Net cash used in operations | $3.71 million | $3.07 million |
At March 31, 2016, cash and cash equivalents were $16.60 million, total current assets were $16.89 million, and net working capital was $10.7 million. Cash declined $4.56 million during the quarter. Total debt, net of discount, was $4.79 million, including $3.30 million current and $1.49 million long-term. The secured term loan carried an 8.20% rate and was scheduled to mature in 2017. Accumulated deficit was $58.70 million. As a clinical-stage company without product sales, the filing does not provide a meaningful revenue margin.
Material Changes Versus the Prior Comparable Period
- R&D expense rose $0.57 million, mainly reflecting ongoing CERC-301 Phase 2 activity and initiation of the CERC-501 smoking-cessation Phase 2 trial.
- G&A expense increased $1.89 million, including higher public-company professional costs and compensation. A $781,266 charge arose from extending the former CEO’s option exercise term.
- Operating loss increased $2.46 million and net loss increased $1.90 million. The reported per-share loss is not directly comparable without considering the change in weighted-average shares, from 649,721 to 8,650,143, following the IPO and capital-structure changes.
- Operating cash use increased $0.64 million. Financing cash use was $0.84 million, primarily due to $0.80 million of term-loan principal payments.
Outlook, Risks, and Unusual Items
- Management expected existing cash to fund operating and capital needs only through the end of 2016. The filing states that recurring losses and negative operating cash flows raise substantial doubt about the company’s ability to continue as a going concern; substantial additional financing would be required.
- Management expected CERC-501 Phase 2 top-line data in Q4 2016. Slower-than-expected enrollment in CERC-301 shifted the anticipated top-line data timing from the second half of 2016 to the first half of 2017.
- On April 11, 2016, Cerecor received notice of an approximately $1.0 million NIH/NIDA research grant for the CERC-501 Phase 2 trial, expected to be received in Q2 2016.
- Key risks include clinical-trial enrollment delays, uncertain trial outcomes and regulatory approval, and inability to obtain financing on acceptable terms. The company also disclosed up to approximately $3.9 million of future contractual obligations for CRO and other external services.
- The company reported no material legal proceedings, no off-balance-sheet arrangements, and effective disclosure controls. Its term loan is secured by company assets other than intellectual property and includes covenants and account-control provisions.
Important Facts to Verify
- Confirm the entity and period: the supplied text identifies Cerecor Inc. and Q1 2016, despite the request metadata naming Avalo Therapeutics.
- Verify subsequent cash receipts, financing, and the actual cash runway, particularly against management’s end-of-2016 estimate and going-concern disclosure.
- Check actual timing and results of the CERC-301 and CERC-501 trials, including enrollment progress and the announced NIH grant receipt.
- Review the term-loan balance, repayment schedule, maturity, and compliance with covenants.
- Assess the effect of the former CEO option modification and other stock-based compensation on reported expenses and potential dilution.